Revenue
2016
2017
2018
2019
2020
2021
2022
2023
AXIM BIOTECHNOLOGIES, INC. (AXIM)
Price—Loading quote
Net income
2016
2017
2018
2019
2020
2021
2022
2023
Free cash flow
2014
2015
2016
2020
2021
2022
2023
Total cash / debt
CashTotal debt
2016
2017
2018
2019
2020
2021
2022
2023
Financial statements
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $39,518 | $8,875 | $60,460 | $0 | $799,483 | $195,614 | $47,573 | $47,059 | $49,139 | $0 | $21,667 | $43,333 | $10,000 |
| Gross profit | — | — | — | $0 | $0 | $187,103 | $4,716 | −$107,071 | −$1,248 | $0 | — | — | — |
| Research & development | $125,496 | $153,697 | $284,869 | $426,708 | $0 | $2.1M | $1.4M | $235,579 | $571,455 | $0 | — | — | — |
| Operating expenses | $2.8M | $4.7M | $14.0M | $4.9M | $3.1M | $5.2M | $3.2M | $3.7M | $10.0M | $505,729 | $62,886 | $58,237 | $12,794 |
| Operating income | −$2.8M | −$4.7M | −$14.0M | −$4.9M | −$3.1M | −$5.0M | −$3.1M | −$3.8M | −$10.0M | −$505,729 | — | — | — |
| EBITDAderived | −$2.3M | −$4.2M | −$11.9M | −$4.9M | −$3.1M | −$5.0M | −$3.1M | −$3.8M | −$10.0M | −$505,729 | — | — | — |
| Net income | −$8.1M | −$6.2M | −$16.0M | −$6.4M | −$6.4M | −$6.8M | −$4.2M | −$5.8M | −$10.1M | −$582,947 | −$89,219 | −$14,904 | −$2,794 |
| Basic EPSper diluted share | -$0.04 | -$0.04 | $0.12 | -$0.06 | -$0.10 | -$0.12 | -$0.08 | -$0.17 | -$0.27 | -$0.02 | $0.00 | — | $0.00 |
| Diluted EPSper diluted share | -$0.04 | -$0.04 | $0.12 | -$0.06 | -$0.10 | -$0.12 | -$0.08 | -$0.17 | -$0.27 | -$0.02 | $0.00 | — | $0.00 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jan 30, 2024Form 4 | Valencia CatalinaPresident and Director | BuyCommon Stock | 1.09M | — | — | 28.61M |